Page 7,046«..1020..7,0457,0467,0477,048..7,0607,070..»

CareFusion To Acquire Pharmacy Automation Technology Leader

Posted: Published on March 6th, 2012

SAN DIEGO, March 6, 2012 /PRNewswire/ --CareFusion today announced an agreement to acquire PHACTS, LLC, a Seattle-based technology and consulting company that helps hospital pharmacies better manage inventory, reduce pharmaceutical costs and streamline operations. Terms of the deal were not disclosed. The acquisition will advance CareFusion's strategy to offer hospitals safe and efficient systems to manage medication throughout their facilities from the loading dock to the patient bedside and through to waste segregation. By adding PHACTS to the company's core Pyxis dispensing technologies portfolio, CareFusion will be able to provide health systems better visibility into drug inventories, helping to reduce on-hand inventory, streamline staff workflow, manage drug shortages and improve financial performance. In November 2010, CareFusion announced a global marketing relationship as the exclusive reseller of PHACTS pharmacy inventory management software and automation. Through this partnership, PHACTS expanded its base of customers by 50 percent to more than 200 customers. "With the addition of PHACTS market-leading products to our portfolio, CareFusion is better positioned to help hospitals realize significant savings, including a reduction in medication inventory on-hand levels by up to 40 percent," said Tom Leonard, president of Medical Systems at CareFusion. "The acquisition will enable us to more directly … Continue reading

Posted in Pharmacy | Comments Off on CareFusion To Acquire Pharmacy Automation Technology Leader

Cord Blood Registry's Leading Science and Research Team – Video

Posted: Published on March 6th, 2012

05-03-2012 11:59 Learn more about cord blood stem cells here http://www.cordblood.com Cord Blood Registry's Scientific and Medical Affairs team, led by Heather Brown Vice President of Scientific and Medical Affairs, is dedicated to helping understand, communicate and advance stem cell medicine. Her team's focus is on helping find new uses for cord blood, including supporting research that is looking for treatments for conditions that have no treatment today. Our company was founded on the belief that saving newborn stem cells can change the future of medicine. Whether it's providing newborn stem cell banking at no cost to a family with a medical need or partnering with world-class researchers for first-of-their-kind clinical trials, we are committed to advancing stem cell medicine and finding new cures. Read the rest here: Cord Blood Registry's Leading Science and Research Team - Video … Continue reading

Comments Off on Cord Blood Registry's Leading Science and Research Team – Video

Penn Medicine Science Educator Recognized by Society for Developmental Biology

Posted: Published on March 6th, 2012

PHILADELPHIA Jamie Shuda, EdD, director of life science outreach at the University of Pennsylvania's Institute for Regenerative Medicine (IRM), and coordinator of life science education at the Netter Center for Community Partnerships also at Penn, along with Steve Farber, PhD, Investigator, Embryology Department, Carnegie Institution for Science, Baltimore, have been awarded the Hamburger Outstanding Educator Prize from the Society for Developmental Biology (SBD). Shuda and Farber run Project BioEYES, a K-12 science education program that provides classroom-based, hands-on learning using live zebrafish to teach about how cells and animals develop. The program is located within the Perelman School of Medicine, Penn; the Carnegie Institution; Notre Dame University in South Bend, IN; and Monash University in Melbourne, Australia, among others, and reaches over 9,000 students per year. "I am honored that the Society for Developmental Biology has chosen me and Dr. Farber as the 2012 recipients of the Viktor Hamburger prize," says Shuda. "Project BioEYES exemplifies how scientists and educators can come together to teach cutting edge, exciting science to students of all ages. Collaboration across disciplines is greatly supported by Penn and the IRM and it is wonderful that the university is being recognized for their public engagement. Viktor Hamburger … Continue reading

Comments Off on Penn Medicine Science Educator Recognized by Society for Developmental Biology

Nuvilex Forecasts Vast Partnership Opportunities Using Breakthrough Stem Cell Technology

Posted: Published on March 6th, 2012

SILVER SPRING, Md.--(BUSINESS WIRE)-- Nuvilex, Inc. (OTCQB:NVLX), an emerging biotechnology provider of cell and gene therapy solutions, today pointed out the potential for substantial partnership and licensing opportunities using the companys cell encapsulation technology for applications in stem cell research and medicine. Migration of implanted cells away from the target site and host rejection have been recognized as fundamental challenges faced by the stem cell community regarding their use in therapy, which the companys technology overcomes. The technology being acquired from associate SG Austria is used to place live stem cells into strong, flexible and permeable capsules. These capsules can then be implanted into animals or humans for specific therapies. Stem cells can then exist at the desired location inside the capsules, prevented from migrating and protected from the immune system that aims to eliminate such foreign cells from the body. Stem cell therapy is being used by clinicians throughout the world for treating such diverse diseases as spinal cord injury, amyotrophic lateral sclerosis, burns, glioma, multiple myeloma, arthritis, heart disease, stroke, Stargardt's Macular Dystrophy, and age-related macular degeneration, among others, most of which can be found at ClinicalTrials.gov. Historically, researchers have faced numerous difficulties in succeeding with certain stem … Continue reading

Posted in Stem Cell Treatments | Comments Off on Nuvilex Forecasts Vast Partnership Opportunities Using Breakthrough Stem Cell Technology

Marshall Edwards Submits Investigational New Drug Application for Oncology Drug Candidate ME-344

Posted: Published on March 6th, 2012

SAN DIEGO, March 6, 2012 /PRNewswire/ --Marshall Edwards, Inc. (Nasdaq: MSHL - News), an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism, announced today that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) to initiate clinical testing for oncology drug candidate ME-344, the Company's lead mitochondrial inhibitor. "I am extremely proud of our clinical operations and pre-clinical research teams in reaching this important milestone, less than seven months since our IND for ME-143 was approved by the FDA to begin clinical testing," said Daniel P. Gold, Ph.D., President and Chief Executive Officer of Marshall Edwards. "We are prepared to initiate a Phase I clinical trial of intravenous ME-344 in patients with solid refractory tumors immediately following approval by the FDA." Marshall Edwards also announced that it has commenced dosing of the fourth cohort in its Phase I clinical trial of intravenous ME-143 in patients with solid refractory tumors. The Company expects to collect final safety and pharmacokinetic data from this trial by June. "We continue to execute on the clinical development plan we set forth for our two most promising drug candidates," said Robert Mass, M.D., … Continue reading

Posted in FDA Stem Cell Trials | Comments Off on Marshall Edwards Submits Investigational New Drug Application for Oncology Drug Candidate ME-344

Medistem Inc. to Add Kidney and Lung Failure to Clinical Trials of Endometrial Regenerative Cells (ERC) Stem Cells in …

Posted: Published on March 6th, 2012

SAN DIEGO, CA and PORTLAND, OR--(Marketwire -03/05/12)- Medistem Inc. (Pinksheets: MEDS.PK - News), in partnership with its Russian licensee, ERCell, announced the signing of a letter of intent* to begin clinical trials using Medistem's Endometrial Regenerative Cells (ERC) stem cells for renal, lung and peripheral artery disease. Trials will be conducted in the S.M. Kirov Military Medical Academy in St. Petersburg, Russia. Under the agreement, Medistem, ERCell and the Academy will work together to a) Design and obtain approval for clinical trials; b) Provide training and execute the trials; and c) Identify opportunities for commercialization of the ERC product through existing military and governmental programs. Under the license agreement, Medistem receives cash and royalty revenues from Russian developmental activities as well as all the data gathered from the trials. According to the agreement, work performed by ERCell will be conducted according to international "Good Clinical Practices" (GCP) so the data gathered can be used for Russian registration as well as to support US FDA submissions. "At Medistem, our philosophy has always been to follow the data. We aim to be as aggressive as possible, to obtain as much data as possible, as quickly as possible," stated Thomas Ichim, CEO of … Continue reading

Posted in Stem Cell Human Trials | Comments Off on Medistem Inc. to Add Kidney and Lung Failure to Clinical Trials of Endometrial Regenerative Cells (ERC) Stem Cells in …

Cryo-Cell's Affiliate, Saneron CCEL Therapeutics, Releases Pre-clinical Data Indicating That Cord Blood Stem Cells …

Posted: Published on March 6th, 2012

Repeated injections of human umbilical cord blood cells improved motor neuron survival, delayed disease progression and increased lifespan Oldsmar, FL (PRWEB) March 06, 2012 Dr. Julie G. Allickson, PhD. Vice President of Laboratory Operations and R&D, stated This groundbreaking study demonstrates the amazing capacity of cord blood stem cells to potentially treat a devastating neurodegenerative disease through the secretion of trophic factors that resulted in neuroprotection in the ALS mouse model. The data certainly justifies additional pre-clinical investigations using umbilical cord blood stem cells. This source of cells has mainly been used in hematopoietic and immune diseases in more than 25,000 transplants to date. Cryo- Cell is excited about the results of the research Saneron CCEL Therapeutics has completed and proud of the progress Saneron has made in the treatment for ALS. The investment community does not appreciate the value of Cryo-Cells holdings in Saneron and its world-class research initiatives, commented David Portnoy, Cryo-Cells Chairman and CEO. Given the delay between the onset of symptoms and the actual diagnosis of ALS, the data obtained from this study was critically important to show that multiple low-doses of cord blood cells started after the symptomatic disease stage in the ALS mouse model … Continue reading

Comments Off on Cryo-Cell's Affiliate, Saneron CCEL Therapeutics, Releases Pre-clinical Data Indicating That Cord Blood Stem Cells …

Influencing stem cell fate: New screening method helps scientists identify key information rapidly

Posted: Published on March 6th, 2012

Researchers can use the method, called nanocombinatorics, to build enormous libraries of physical structures varying in size from a few nanometers to many micrometers for addressing problems within and outside biology. Those in the fields of chemistry, materials engineering and nanotechnology could use this invaluable tool to assess which chemical and physical structures -- including size, shape and composition -- work best for a desired process or function. Nanocombinatorics holds promise for screening catalysts for energy conversion, understanding properties conferred by nanostructures, identifying active molecules for drug discovery or even optimizing materials for tissue regeneration, among other applications. Details of the method and proof of concept is published in the Proceedings of the National Academy of Sciences. "With further development, researchers might be able to use this approach to prepare cells of any lineage on command," said Chad A. Mirkin, who led the work. "Insight into such a process is important for understanding cancer development and for developing novel cancer treatment methodologies." Mirkin is the George B. Rathmann Professor of Chemistry in the Weinberg College of Arts and Sciences and professor of medicine, chemical and biological engineering, biomedical engineering and materials science and engineering. He also is the director of … Continue reading

Comments Off on Influencing stem cell fate: New screening method helps scientists identify key information rapidly

UNC Hospitals preps for triple-tandem stem cell transplant

Posted: Published on March 6th, 2012

CHAPEL HILL, N.C. -- A Carrboro man is getting the first triple-tandem stem cell transplant performed at UNC Hospitals to treat a testicular cancer recurrence. David Alston was diagnosed with testicular cancer a year ago. He went through chemotherapy at UNC and thought he'd beat it, but doctors discovered the cancerhad come back during a routine blood test. "I was devastated", said Alston. "I completely fell apart." He found hope again when Dr. Paul Armstead at UNC Hospitalssuggested a treatment that involved stem cell transplants. "It's good for someone young like David whose already tolerated all the chemotherapy we've given him," said Dr. Armstead. "We think this is his best chance of being cured of this disease." Alston's stem cells were recovered in a process that Alston says is like giving blood. "Once we give a high dose of chemotherapy we then take some of his frozen bone marrow stem cells and give those back to him," explained Dr. Armstead. "This allows his blood count to recover and that's transplant number one." Alston's treatment is unique because he'll receive three transplants. It's a process that will keep him in the hospital for about nine weeks and take a major toll … Continue reading

Comments Off on UNC Hospitals preps for triple-tandem stem cell transplant

Influencing stem cell fate

Posted: Published on March 6th, 2012

Public release date: 6-Mar-2012 [ | E-mail | Share ] Contact: Megan Fellman fellman@northwestern.edu 847-491-3115 Northwestern University Northwestern University scientists have developed a powerful analytical method that they have used to direct stem cell differentiation. Out of millions of possibilities, they rapidly identified the chemical and physical structures that can cue stem cells to become osteocytes, cells found in mature bone. Researchers can use the method, called nanocombinatorics, to build enormous libraries of physical structures varying in size from a few nanometers to many micrometers for addressing problems within and outside biology. Those in the fields of chemistry, materials engineering and nanotechnology could use this invaluable tool to assess which chemical and physical structures -- including size, shape and composition -- work best for a desired process or function. Nanocombinatorics holds promise for screening catalysts for energy conversion, understanding properties conferred by nanostructures, identifying active molecules for drug discovery or even optimizing materials for tissue regeneration, among other applications. Details of the method and proof of concept is published in the Proceedings of the National Academy of Sciences. "With further development, researchers might be able to use this approach to prepare cells of any lineage on command," said Chad A. … Continue reading

Comments Off on Influencing stem cell fate

Page 7,046«..1020..7,0457,0467,0477,048..7,0607,070..»